AR079654A1 - Combinaciones anticancerosas de farmacos a base de artemisinina y otros agentes quimioterapeuticos. uso. composicion farmaceutica. procedimiento de preparacion. metodo de tratamiento. - Google Patents
Combinaciones anticancerosas de farmacos a base de artemisinina y otros agentes quimioterapeuticos. uso. composicion farmaceutica. procedimiento de preparacion. metodo de tratamiento.Info
- Publication number
- AR079654A1 AR079654A1 ARP100104807A ARP100104807A AR079654A1 AR 079654 A1 AR079654 A1 AR 079654A1 AR P100104807 A ARP100104807 A AR P100104807A AR P100104807 A ARP100104807 A AR P100104807A AR 079654 A1 AR079654 A1 AR 079654A1
- Authority
- AR
- Argentina
- Prior art keywords
- camptothecin
- iminomethylcamptothecin
- chemotherapeutic
- agent
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a combinaciones entre potentes agentes antipaludicos a base de artemisinina, seleccionados entre el grupo compuesto por ART, DHA y ARM, y otro fármaco quimioterapéutico seleccionado entre el grupo compuesto por un derivado de camptotecina, un inhibidor de PARP-1, un agente intercalante o un agente alquilante. Dichas combinaciones mostraron un sinergismo medio a fuerte en varios modelos de cáncer, en particular, NSCL. Reivindicacion 1: Una combinacion quimioterapéutica compuesta por: un agente farmacéutico (a) seleccionado entre el grupo integrado por ART, DHA y ARM; y un agente quimioterapéutico (b) seleccionado entre el grupo integrado por derivados de camptotecina que son seleccionados entre el grupo compuesto por 7-metoxiiminometilcamptotecina, 7-metoxiiminometil-10-hidroxicamptotecina, 7-(terc-butoxicarbonil-2-propoxi)-iminometilcamptotecina, 7-etoxiiminometilcamptotecina, 7-isopropoxi-iminometilcamptotecina, 7-(2-metilbutoxi)-iminometilcamptotecina, 7-t-butoxiiminometilcamptotecina, 7-t-butoxiiminometil-10-hidroxicamptotecina, 7-t-butoxiiminometil-10-metoxicamptotecina, 7-(4-hidroxi-butoxi)-iminometilcamptotecina, 7-trifenil-metoxiiminometilcamptotecina, 7-carboximetoxiiminometilcamptotecina, 7-(2-amino)-etoxiiminometil-camptotecina, 7-(2-N,N-dimetilamino)-etoxiiminometilcamptotecina, 7-aliloxiiminometil-camptotecina, 7-ciclohexiloxiiminometilcamptotecina, 7-ciclohexilmetoxiiminometilcamptotecina, 7-ciclooctiloxiiminometilcamptotecina, 7-ciclooctilmetoxiiminometilcamptotecina, 7-benciloxi-iminometilcamptotecina, 7-[(1-benciloxiimino)-2-feniletil]camptotecina, 7-(1-benciloxi-imino)-etilcamptotecina, 7-fenoxi-iminometilcamptotecina, 7-(1-t-butoxiimino)-etilcamptotecina, 7-p-nitrobenciloxiiminometilcamptotecina, 7-p-metilbenciioxiiminometilcamptotecina, 7-pentafluorobenciloxiiminometil-camptotecina, 7-p-fenilbenciloxiiminometilcamptotecina, 7-[2-(2,4-difluorofenii)-etoxi]iminometilcamptotecina, 7-(4-t-butilbenciloxi)-iminometilcamptotecina, 7-(1-adamantiloxi)-iminometilcamptotecina, 7-(1-adamantilmetoxi)-iminometilcamptotecina, 7-(2-naftiloxi)-iminometilcamptotecina, 7-(9-antrilmetoxi)-iminometilcamptotecina, 7-oxiranilmetoxiiminometil-camptotecina, 7-(6-uracil)-metoxiiminometilcamptotecina, 7-[2-(1-uracil)-etoxi]-iminometilcamptotecina, 7-(4-piridil)-metoxiiminometil-camptotecina, 7-(2-tienil)-metoxiiminometil-camptotecina, 7-[(N-metil)-4-piperidinil]-metoxiiminometilcamptotecina, 7-[2-(4-morfolininil]-etoxi]-iminometilcamptotecina, 7-(benciloxiiminometil)-camptotecina, 7-[(1-hidroxiimino)-2-feniletil)-camptotecina, N-oxido de 7-terc-butiloxi-iminometil-camptotecina, N-oxido de 7-metoxiiminometilcamptotecina, irinotecán y su metabolito activo SN-38; inhibidores de PARP-1, agentes intercalantes y agentes alquilantes; donde dentro de dicha combinacion, cada ingrediente (a) y (b) se formula separado del otro o se formulan en una forma de dosificacion unitaria. Reivindicacion 6: La combinacion quimioterapéutica de acuerdo con la reivindicacion 5, caracterizada porque el derivado de camptotecina se selecciona entre el grupo compuesto por 7-t-butoxiiminometilcamptotecina, 7-benciloxi-iminometiicamptotecina, 7-(2-amino)-etoxiiminometil-camptotecina, irinotecán y su metabolito activo SN-38. Reivindicacion 7: La combinacion quimioterapéutica de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizada porque el agente quimioterapéutico (b) es un inhibidor de PARP-1. Reivindicacion 8: La combinacion quimioterapéutica de acuerdo con la reivindicacion 7, caracterizada porque el inhibidor de PARP-1 es fenantridinona, AZD2281 o ABT 888. Reivindicacion 9: La combinacion quimioterapéutica de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizada porque e] agente quimioterapéutico (b) es un agente intercalante o un agente alquilante. Reivindicacion 11: El uso de acuerdo con la reivindicacion 10 para la preparacion de un medicamento para la prevencion y/o tratamiento de un neoplasma. Reivindicacion 14: Una composicion farmacéutica que comprende una combinacion quimioterapéutica de acuerdo con cualquiera de las reivindicaciones 1 a 9 y al menos un portador y/o excipiente y/o diluyente farmacéuticamente aceptable; donde el agente farmacéutico (a) y el agente quimioterapéutico (b) están presentes en una forma de una unica dosificacion o en dos formas de dosificacion separadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09180666 | 2009-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079654A1 true AR079654A1 (es) | 2012-02-08 |
Family
ID=41647059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104807A AR079654A1 (es) | 2009-12-23 | 2010-12-21 | Combinaciones anticancerosas de farmacos a base de artemisinina y otros agentes quimioterapeuticos. uso. composicion farmaceutica. procedimiento de preparacion. metodo de tratamiento. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9023861B2 (es) |
| EP (1) | EP2515898A1 (es) |
| JP (1) | JP2013515690A (es) |
| KR (1) | KR20120096053A (es) |
| CN (1) | CN102665711A (es) |
| AR (1) | AR079654A1 (es) |
| AU (1) | AU2010335422A1 (es) |
| BR (1) | BR112012015606A2 (es) |
| CA (1) | CA2780591A1 (es) |
| EA (1) | EA201200934A1 (es) |
| IL (1) | IL220561A0 (es) |
| IN (1) | IN2012DN03914A (es) |
| MX (1) | MX2012006738A (es) |
| MY (1) | MY157475A (es) |
| NZ (1) | NZ599878A (es) |
| SG (1) | SG10201408485SA (es) |
| TW (1) | TWI482621B (es) |
| UA (1) | UA107691C2 (es) |
| WO (1) | WO2011076547A1 (es) |
| ZA (1) | ZA201205360B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| US9801851B2 (en) * | 2012-05-23 | 2017-10-31 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias |
| EP3137076A4 (en) * | 2014-05-02 | 2017-12-06 | Emory University | Selective chemotherapy treatments and diagnostic methods related thereto |
| US9918972B2 (en) * | 2014-12-23 | 2018-03-20 | The University Of Maryland, Baltimore | Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents |
| CN105963262B (zh) * | 2016-06-06 | 2018-11-30 | 北京林业大学 | 一种两亲性果胶-双氢青蒿素纳米粒子的制备方法 |
| CN110051850A (zh) * | 2016-08-26 | 2019-07-26 | 宁国市厚普生物科技有限公司 | 一种复合物在制备用于治疗黑色素瘤的药物中的应用 |
| CN109453156A (zh) * | 2018-11-22 | 2019-03-12 | 中国中医科学院中药研究所 | 一种抗肿瘤组合物及其应用、抗肿瘤药物 |
| CN114053276A (zh) * | 2020-07-30 | 2022-02-18 | 江苏天士力帝益药业有限公司 | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 |
| CN114053271A (zh) * | 2020-07-30 | 2022-02-18 | 江苏天士力帝益药业有限公司 | 一种含有tsl-1502m的药物组合物及其应用 |
| CN114010643A (zh) * | 2021-11-23 | 2022-02-08 | 温州医科大学 | 双氢青蒿素在抗肿瘤药物的制备中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578637A (en) | 1995-05-03 | 1996-11-26 | University Of Washington | Methods of inhibition or killing cancer cells using an endoperoxide |
| DE69901379T2 (de) | 1999-03-09 | 2002-11-07 | Sigma Tau Ind Farmaceuti | Camptothecin-Derivate mit Antitumor-Wirkung |
| KR100390332B1 (ko) | 2000-08-02 | 2003-07-07 | 유원민 | 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물 |
| DE602004029651D1 (de) | 2003-02-12 | 2010-12-02 | Univ Georgetown | Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen |
| EP1658844A1 (en) | 2004-10-19 | 2006-05-24 | Gerold Schuler | Use of artemisinin derivatives in the manufacture of a medicament for the treatment of melanoma |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US8143284B2 (en) * | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
| NZ576693A (en) | 2006-11-20 | 2011-12-22 | Cephalon Inc | Method of radio-sensitizing tumors using 4-methoxy-carbazoles compounds |
| CN101125140B (zh) * | 2007-09-18 | 2011-04-13 | 浙江大学 | 二氢青蒿素在制备增强化疗药物抗肿瘤疗效的药物中的应用 |
| WO2009114459A2 (en) * | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein |
| CN101380325A (zh) * | 2008-10-23 | 2009-03-11 | 上海交通大学 | 青蒿素衍生物与长春瑞滨的组合物及其应用 |
| CN101428034B (zh) * | 2008-12-12 | 2012-02-08 | 广州市允中投资发展有限公司 | 具有增效减毒特点的抗肿瘤组合药物 |
| CN101856352A (zh) * | 2009-04-10 | 2010-10-13 | 中国科学院上海生命科学研究院 | 青蒿素及其衍生物对化疗剂的协同作用 |
-
2010
- 2010-11-22 TW TW099140203A patent/TWI482621B/zh not_active IP Right Cessation
- 2010-12-06 BR BR112012015606A patent/BR112012015606A2/pt not_active IP Right Cessation
- 2010-12-06 CA CA2780591A patent/CA2780591A1/en not_active Abandoned
- 2010-12-06 KR KR1020127016599A patent/KR20120096053A/ko not_active Application Discontinuation
- 2010-12-06 NZ NZ599878A patent/NZ599878A/en not_active IP Right Cessation
- 2010-12-06 EA EA201200934A patent/EA201200934A1/ru unknown
- 2010-12-06 SG SG10201408485SA patent/SG10201408485SA/en unknown
- 2010-12-06 AU AU2010335422A patent/AU2010335422A1/en not_active Abandoned
- 2010-12-06 UA UAA201208932A patent/UA107691C2/ru unknown
- 2010-12-06 MY MYPI2012001992A patent/MY157475A/en unknown
- 2010-12-06 WO PCT/EP2010/068924 patent/WO2011076547A1/en active Application Filing
- 2010-12-06 JP JP2012545201A patent/JP2013515690A/ja not_active Ceased
- 2010-12-06 US US13/518,185 patent/US9023861B2/en not_active Expired - Fee Related
- 2010-12-06 MX MX2012006738A patent/MX2012006738A/es not_active Application Discontinuation
- 2010-12-06 IN IN3914DEN2012 patent/IN2012DN03914A/en unknown
- 2010-12-06 CN CN2010800580524A patent/CN102665711A/zh active Pending
- 2010-12-06 EP EP10788312A patent/EP2515898A1/en not_active Withdrawn
- 2010-12-21 AR ARP100104807A patent/AR079654A1/es unknown
-
2012
- 2012-06-21 IL IL220561A patent/IL220561A0/en unknown
- 2012-07-18 ZA ZA2012/05360A patent/ZA201205360B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120258181A1 (en) | 2012-10-11 |
| UA107691C2 (ru) | 2015-02-10 |
| JP2013515690A (ja) | 2013-05-09 |
| MY157475A (en) | 2016-06-15 |
| KR20120096053A (ko) | 2012-08-29 |
| EA201200934A1 (ru) | 2012-12-28 |
| IL220561A0 (en) | 2012-08-30 |
| MX2012006738A (es) | 2012-07-03 |
| ZA201205360B (en) | 2013-05-29 |
| BR112012015606A2 (pt) | 2018-05-29 |
| CA2780591A1 (en) | 2011-06-30 |
| AU2010335422A1 (en) | 2012-06-07 |
| IN2012DN03914A (es) | 2015-09-04 |
| US9023861B2 (en) | 2015-05-05 |
| TWI482621B (zh) | 2015-05-01 |
| WO2011076547A1 (en) | 2011-06-30 |
| EP2515898A1 (en) | 2012-10-31 |
| CN102665711A (zh) | 2012-09-12 |
| SG10201408485SA (en) | 2015-01-29 |
| TW201138764A (en) | 2011-11-16 |
| NZ599878A (en) | 2014-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079654A1 (es) | Combinaciones anticancerosas de farmacos a base de artemisinina y otros agentes quimioterapeuticos. uso. composicion farmaceutica. procedimiento de preparacion. metodo de tratamiento. | |
| AU2018256624A1 (en) | JAK2 and ALK2 inhibitors and methods for their use | |
| HRP20160605T1 (hr) | Tetraciklički spoj | |
| PE20220581A1 (es) | Composicion farmaceutica para suministro nasal | |
| JP2019501195A5 (ja) | 腫瘍を処置するための抗ｅｇｆｒ組み合わせ | |
| TN2016000090A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors. | |
| EP3251674A3 (en) | Antiviral azasugar-containing nucleosides | |
| UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
| JP2014511892A5 (es) | ||
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| AR049540A1 (es) | Derivados de quinazolindiona como inhibidores del parp; metodos para su preparacion; composiciones farmaceuticas que los contienen como ingrediente activo y su uso en medicamentos para el tratamiento o prevencion del cancer. | |
| WO2005086700A3 (en) | Hiv integrase inhibitors | |
| RS54339B1 (en) | NEW ANTIMALARIAN AGENTS | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| JP2019501196A5 (ja) | 腫瘍を処置するための抗ｃｄ２０組み合わせ | |
| JP2006508953A5 (es) | ||
| CA2611474A1 (en) | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor | |
| DK2997033T3 (da) | Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere | |
| EA200870545A1 (ru) | Новые гетероциклические соединения | |
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| RU2013122656A (ru) | Композиции и способы доставки терапевтических средств | |
| WO2007035121A3 (en) | Isoflavones for treating mucopolysaccharidoses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |